Picture of Abbott Laboratories logo

ABT Abbott Laboratories Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Annual cashflow statement for Abbott Laboratories, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line2,3683,6874,4957,0716,933
Depreciation
Amortisation
Non-Cash Items802766971695900
Discontinued Operations
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-148-1,331-892-771-1,519
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Payable / Accrued Expenses
Change in Taxes Payable
Cash from Operating Activities6,3006,1367,90110,5339,581
Capital Expenditures-1,394-1,638-2,177-1,885-1,777
Purchase of Fixed Assets
Other Investing Cash Flow Items38-177-38-12337
Acquisition of Business
Sale of Business
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-1,356-1,815-2,215-2,008-1,740
Financing Cash Flow Items00-110
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities-10,391-4,289-2,779-5,494-7,636
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-5,563162,9782,96183

Or unlock with your email

Or unlock with your email